Reversal effects of mifepristone on multidrug resistance(MDR) in drug-resistant breast cancer cell line MCF7/ADR in vitro and in vivo

Chinese Journal of Cancer Research

Volumn 16, Issue 2, 2004, Pages 93-98

  Li, Da Qiang ^a   Pan, Li Hua ^b   Shao, Zhi Min ^a  

^a FUDAN UNIVERSITY   (China)

^b CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; Mifepristone; Multidrug resistance(MDR)

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; GLYCOPROTEIN P; MESSENGER RNA; MIFEPRISTONE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; RHODAMINE 123; VINCRISTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG MECHANISM; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LIQUID SCINTILLATION COUNTING; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; NUDE MOUSE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR XENOGRAFT; WESTERN BLOTTING;

EID: 3142593936     PISSN: 10009604     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11670-004-0004-z     Document Type: Article

References (21)

1. Osteen RT. Breast Cancer[M]. In: Lenhard RE, Osteen RT, Gansler T, eds. Clinical Oncology. 3rd ed. Oxford: Blackwell Science Ltd. 2003; 251-68.
2. Leonessa F, Clarke R. ATP binding cassette transporters and drug resistance in breast cancer[J]. Endocr Relat Cancer 2003; 10: 43-73.
3. Devarajan E, Chen J, Multani AS, et al. Human breast cancer MCF-7 cell line contains inherently drug-resistant subclones with distinct genotypic and phenotypic features[J]. Int J Oncol 2002; 20: 913-20.
4. Zhang Y, Berger SA. Ketotifen reverses MDR1-mediated multidrug resistance in human breast cancer cells in vitro and alleviates cardiotoxicity induced by doxorubicin in vivo[J]. Cancer Chemother Pharmacol 2003; 51: 407-14.
5. Mahajan DK, London SN. Mifepristone(RU486): a review[J]. Fertil Steril 1997; 68: 967-76.
6. Payen L, Delugin L, Courtois A, et al. Reversal of MRP -mediated multidrug resistance in human lung cancer cells by the antiprogestatin drug RU486[J]. Biochem Biophys Res Commun 1999; 258: 513-8.
7. Gruol DJ, Zee MC, Trotter J, et al. Reversal of multidurg resistance by RU486[J]. Cancer Res 1994; 54: 3088-91.
8. Cole SP, Bhardwaj G, Gerlach H, et al. Overexpression of a transporter gene in multidrug-resistant human lung cancer cell line[J]. Science 1992; 258: 1650-4.
9. Endo K, Maehara Y, Kusumoto T, et al. Expression of multidrug-resistance- associated protein(MRP) and chemosensitivity in human gastric cancer[J]. In J Cancer 1996; 68: 372-7.
10. Zampieri L, Bianchi P, Ruff P, et al. Differential modulation by estradiol of P-glycoprotein drug resistance protein expression in cultured MCF7 and T47D breast cancer cells[J]. Anticancer Res 2002; 22: 2253-59.
11. Del Bufalo D, Biroccio A, Trisciuoglio D, et al. Bcl-2 has differing effects on the sensitivity of breast cancer cells depending on the antineoplastic drug used[J]. Eur J Cancer 2002; 38: 2455-62.
12. Burger H, Foekens JA, Look MP, et al. RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response[J]. Clin Cancer Res 2003; 9: 827-36.
13. Shabbits JA, Mayer LD. P-glycoprotein modulates ceramide-mediated sensitivity of human breast cancer cells to tubulin-binding anticancer drugs[J]. Mol Cancer Ther 2002; 1: 205-13.
14. Zampieri L, Bianchi P, Ruff P, et al. Differential modulation by estradiol of P-glycoprotein drug resistance protein expression in cultured MCF7 and T47D breast cancer cells[J]. Anticancer Res 2002; 22: 2253-9.
15. Sauer G, Kafka A, Grundmann R, et al. Basal expression of the multidrug resistance gene 1 (MDR-1) is associated with the TT genotype at the polymorphic site C3435T in mammary and ovarian carcinoma cell lines[J]. Cancer Lett 2002; 185: 79-85.
16. Filipits M, Malayeri R, Suchomel RW, et al. Expression of the multidrug resistance protein (MRP1) in breast cancer[J]. Anticancer Res 1999; 19: 5043-9.
17. Yang X, Uziely B, Groshen S, et al. MDR1 gene expression in primary and advanced breast cancer[J]. Lab Invest 1999; 79: 271-80.
18. Nakamura T, Oka M, Aizawa K, et al. Direct interaction between a quinoline derivative, MS-209, and multidrug resistance protein(MRP) in human gastric cancer cells[J]. Biochem Biophys Res Commun 1999; 255: 618-24.
19. Fardel O, Courtois A, Drenou B, et al. Inhibiton of P-glycoprotein activity in human leukemic cells by mifepristone[J]. Anticancer Drugs 1996; 7: 671-7.
20. El Etreby MF, Liang Y. Effect of antiprogestins and tamoxifen on growth inhibition of MCF-7 human breast cancer cells in nude mice[J]. Breast Cancer Res Treat 1998; 49: 109-17.
21. Thomas M, Monet JD. Combined effects of RU486 and tamoxifen on the growth and cell cycle phases of the MCF-7 cell line[J]. J Clin Endocrinol Metab 1992; 75: 865-70.